Boston Scientific 2026 Guidance Revision Due to Market Headwinds in Urology & EP

Reasons for Boston Scientific’s 2026 revenue and EPS guidance revision (headwinds in EP/WATCHMAN Urology)

Boston Scientific revised down its 2026 revenue and EPS outlook, citing “unanticipated headwinds and changing business patterns,” and explicitly tying the guidance reduction to challenges concentrated in its EP/WATCHMAN and Urology businesses. ¹

1) WATCHMAN: decelerating procedures driven by tougher comps and a shift from stand-alone to concomitant

Management described WATCHMAN’s near-term headwind as a downturn in volume trends that emerged after strong growth earlier in 2026:

• Volume pressure began in early/mid-February, with declining WATCHMAN volume “for the first time” after initially strong trends earlier in the year. ²
• The company attributes this to strong concomitant growth coming alongside a deceleration in stand-alone WATCHMAN (i.e., mix/shift rather than total demand collapsing). ²
• In the U.S., WATCHMAN grew 19% organically in Q1, but was below expectations, with management attributing pressure on U.S. volumes to annualization of an initial concomitant adoption tailwind plus softening in stand-alone WATCHMAN cases. ³
• Management also pointed to hospital capacity constraints (procedure prioritization) and evolving reimbursement dynamics contributing to the stand-alone softness. ³
• For full-year 2026, Boston Scientific lowered its outlook for WATCHMAN growth, expecting global WATCHMAN growth to be mid-teens and low-to-mid teens in the U.S. ³

Bottom line: the guidance reduction reflects the assumption that the stand-alone WATCHMAN implant business will remain under pressure relative to earlier expectations, even as concomitant demand remains a positive offset. ²³

2) EP (part of the “WATCHMAN EP” area): increased competitive dynamics, implying less growth than previously expected in the U.S.

While Boston Scientific reported strong EP performance in Q1 and defended its long-term PFA leadership, it still reduced U.S./global growth expectations for the EP business into 2026:

• Management said EP/WATCHMAN discussion would pivot to the EP area, highlighting “challenges right now in Urology,” but the guidance context is clearly intertwined with EP/WATCHMAN dynamics. ⁴
• For the EP segment specifically, Boston Scientific reported strong Q1 growth—22% globally (18% U.S., 30% internationally). ⁵
• However, the company updated the full-year EP growth rate to ~10% globally in 2026, and mid-single-digit U.S. growth while international growth was expected to be +20% (including an approximately $35M impact from the discontinuation of POLARx). ⁵
• Management characterized the reduced EP outlook as reflecting “ongoing competitive dynamics” (and also strength in the evolving FARAPULSE PFA catheter/mapping portfolio as a partial offset). ⁵
• In addition, management explicitly stated it is seeing increased competition from other large players (Medtronic, J&J, Abbott), and that it now expects “a bit more share erosion than we anticipated earlier in the year.” ⁶

Bottom line: even though EP growth fundamentals were solid (especially internationally), competitive pressure and share erosion—most evident in the U.S. outlook—contributed to the guidance reset. ⁵⁶

3) Urology: weak Q1 and below-market full-year growth (stone management and single neuromodulation underperformance)

The most direct “headwind” callout for 2026 guidance reduction was Urology performance, described as below expectations in Q1 and expected to remain below market through 2026:

• Boston Scientific said Urology had a difficult Q1, with 1% organic sales growth, falling short of expectations, driven primarily by the stone management and single neuromodulation businesses. ⁷
• For Stone, underperformance was driven by China VBP and product gaps in the core Stone portfolio. ⁷
• Management later reiterated that EP/WATCHMAN Urology is where challenges are most evident: they were “not happy with the 1% growth in the quarter,” and acknowledged they have plans to improve in 2026, but not at the level expected for the business. ⁴
• For the full year, management said Urology would be a below-market year, with full-year uro growth now expected to be low to mid-single digits in 2026. ⁸⁹

Bottom line: Urology underperformance (stones in China due to VBP plus stone product gaps; weakness in single neuromodulation) is a key reason the overall company guidance was reduced. ⁷⁴⁸

4) How these headwinds translate into revised company guidance (revenue and EPS)

The guidance revision was framed as a company-wide response to those business-pattern changes:

• Boston Scientific reduced 2026 guidance, guiding to organic growth of 6.5% to 8% for full year and reducing full-year guidance due to “unanticipated headwinds and changing business patterns.” ¹
• The company also reduced full-year adjusted EPS guidance to $3.34 to $3.41, and described this as representing growth of 9% to 11%. ¹
• In discussing the “guide down,” management highlighted three contributors focused on EP, WATCHMAN, and Urology. ⁹
• For WATCHMAN, management referenced declining stand-alone growth trends and guided conservatively to assume continuation into the guidance period. ²⁹
• For EP, management’s narrative included confidence in PFA leadership but still acknowledged share/competition pressures and updated growth expectations (globally ~10%, U.S. mid-single digits). ⁵⁹⁶
• For Urology, management directly characterized 2026 as below-market (low-to-mid single-digit growth). ⁹⁸

Summary (direct answer)

Boston Scientific revised its 2026 revenue and EPS guidance primarily because EP/WATCHMAN Urology headwinds emerged in the form of:

1. WATCHMAN stand-alone procedure softness after early 2026 strength—driven by annualization of concomitant adoption tailwinds, hospital capacity/procedure prioritization, evolving reimbursement, and a shift toward concomitant cases. ²³
2. EP outlook pressure from increased competition and share erosion, leading to an updated EP growth expectation of ~10% globally and mid-single-digit U.S. growth (despite strong Q1). ⁵⁶
3. Urology underperformance, including stone management issues (notably China VBP and product gaps) and single neuromodulation softness, resulting in low-to-mid single-digit Urology growth and a below-market year expectation. ⁷⁴⁸⁹

These items were explicitly grouped by management as the major contributors to the “guide down” in 2026. ⁹